Artgen Biotech PJSC (MIC:ABIO) EV-to-EBIT : 49.39 (As of Jun. 20, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Artgen Biotech PJSC's Enterprise Value is ₽6,192 Mil. Artgen Biotech PJSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was ₽125 Mil. Therefore, Artgen Biotech PJSC's EV-to-EBIT for today is 49.39.

The historical rank and industry rank for Artgen Biotech PJSC's EV-to-EBIT or its related term are showing as below:

MIC:ABIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -62.08 Med: 20.69 Max: 122.49
Current: 49.39

During the past 13 years, the highest EV-to-EBIT of Artgen Biotech PJSC was 122.49. The lowest was -62.08. And the median was 20.69.

MIC:ABIO's EV-to-EBIT is ranked worse than
85.19% of 432 companies
in the Biotechnology industry
Industry Median: 8.975 vs MIC:ABIO: 49.39

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Artgen Biotech PJSC's Enterprise Value for the quarter that ended in Jun. 2023 was ₽8,597 Mil. Artgen Biotech PJSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was ₽125 Mil. Artgen Biotech PJSC's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 1.46%.

Artgen Biotech PJSC EV-to-EBIT Historical Data

The historical data trend for Artgen Biotech PJSC's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC EV-to-EBIT Chart

Artgen Biotech PJSC Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-35.91

10.27

25.77

113.01

60.16

Artgen Biotech PJSC Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial															-	113.01	-	60.16	-

Competitive Comparison of Artgen Biotech PJSC's EV-to-EBIT

For the Biotechnology subindustry, Artgen Biotech PJSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artgen Biotech PJSC's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's EV-to-EBIT falls into.

Artgen Biotech PJSC EV-to-EBIT Calculation

Artgen Biotech PJSC's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	6192.044	/	125.365
	=	49.39

Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was ₽125 Mil.

Artgen Biotech PJSC (MIC:ABIO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Artgen Biotech PJSC's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	125.365	/	8597.316902
	=	1.46 %

Artgen Biotech PJSC's Enterprise Value for the quarter that ended in Jun. 2023 was ₽8,597 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was ₽125 Mil.

Artgen Biotech PJSC EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Artgen Biotech PJSC (MIC:ABIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Prospect of the 60th Anniversary, Moscow, RUS, 117036

Website

https://www.hsci.ru

Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.